Comparable stake leader
Lynx1 Capital Management LP
SEC ownership of GH Research PLC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001855129.
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- GHRS on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Lynx1 Capital Management LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Lynx1 Capital Management LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001855129
- Issuer location
- Dublin 2, Ireland
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of GH Research PLC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 19%
13D/G row: Lynx1 Capital Management LP
Showing 1-8 of 50 holder rows.
Quick read
Lynx1 Capital Management LP leads the comparable SEC ownership view at 19%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership
Top 5
Lynx1 Capital Management LP
19%
BIOTECHNOLOGY VALUE FUND L P
14%
RTW INVESTMENTS, LP
8.9%
FMR LLC
8.2%
RA CAPITAL MANAGEMENT, L.P.
7.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
13D/G
13F
Company
|
19%
|
$356,649,814
13,263,288 shares
|
+$67,225,000 | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
14%
|
$84,128,095
8,827,712 shares
|
$0 | 31 Mar 2025 |
| RTW INVESTMENTS, LP |
13F
13D/G
Company
|
8.9%
from 13D/G
|
$159,500,947
5,933,815 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13F
13D/G
Company
|
8.2%
from 13D/G
|
$160,662,969
5,977,045 shares
|
— | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
7.1%
from 13D/G
|
$205,277,533
7,636,813 shares
|
— | 30 Jun 2026 |
| Terwey Theis H. |
13D/G
|
2.9%
|
$25,515,004
1,784,266 shares
|
-$41,593,509 | 30 Sep 2025 |
| Florian Schonharting |
3/4/5
Director
|
22%
|
$188,270,121
14,824,419 shares
|
— | 01 Apr 2026 |
| Magnus Clemensen Halle |
3/4/5
Managing Director, Ireland
|
0.17%
|
$1,503,095
118,354 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 30 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-8 of 8 reporting-owner rows connected to GH Research PLC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
8
Largest Forms 3/4/5 holder
Florian Schonharting
Net 12M change
$0
Latest report
11 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Florian Schonharting | Director | $188,270,121 | Mixed | 01 Apr 2026 | ||
| Magnus Clemensen Halle | Managing Director, Ireland | $1,503,095 | Mixed | 18 Mar 2026 | ||
| Michael Forer | Director | $577,964 | Mixed | 11 Aug 2026 | ||
| Duncan Moore | Director | $195,494 | Mixed | 11 Aug 2026 | ||
| Dermot John Hanley | Director | $30,886 | Mixed | 11 Aug 2026 | ||
| Velichka Valcheva | Chief Executive Officer | Mixed | 18 Mar 2026 | |||
| Julie Ryan | VP, Finance | Mixed | 18 Mar 2026 | |||
| Aaron Luke Cameron | Chief Operating Officer | Mixed | 18 Mar 2026 |
Recent insider transactions for GH Research PLC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Duncan Moore | GHRS | Share Options (Right to Buy) | Award | 2,202 | 2,202 | 11 Aug 2026 | Direct | |||
| Dermot John Hanley | GHRS | Share Options (Right to Buy) | Award | 2,202 | 2,202 | 11 Aug 2026 | Direct | |||
| Michael Forer | GHRS | Share Options (Right to Buy) | Award | 102,202 | 100,000 | 11 Aug 2026 | Direct |
* marks a reported price that did not pass the local price check.